acetimidamide | 27757-71-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: acetimidamide
• 英文别名: 2-aminoethanimidamide；Aminoacetamidin；α-Amino-acetamidin；2-amino-acetamidine；2-Amino-acetamidin；Glycin-(amid-imid)；aminoacetamidine
• CAS: 27757-71-7
• 化学式: C₂H₇N₃
• 分子量: 73.0977
• InChiKey: SVFHHGXDLUSTKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  5
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.9
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  acetimidamide 在 二氯化二硫 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1,2,5-噻二唑-3-胺
  参考文献：
  名称：

  General synthetic system for 1,2,5-thiadiazoles

  摘要：

  DOI：

  10.1021/jo01284a040
• 作为产物：
  描述：

  脒甲基胺甲酸苄酯盐酸盐 在 硝基甲烷 、 乙醇 、 氢溴酸 作用下， 生成 acetimidamide
  参考文献：
  名称：

  Mengelberg, Chemische Berichte, 1956, vol. 89, p. 1185,1193

  摘要：

  DOI：

文献信息

• Pyrazinone N-oxide nucleosides and analogs thereof
  申请人：Research Foundation of State of N.Y.

  公开号：US05192764A1

  公开（公告）日：1993-03-09

  This invention relates to nucleoside and acyclo analogs containing 5- or 6-substituted 2-pyrazinone-4-N-oxide. These compounds are useful for treating various conditions including viral infections, cancer, fungal infections, bacterial infections, microbial infections and related disease states. This invention also relates to pharmaceutical formulations containing these compounds. In addition, this invention relates to methods of treating the above-described conditions in animals and in particular, humans.

  本发明涉及含有5-或6-取代的2-吡唑酮-4-N-氧化物的核苷和非环式类似物。这些化合物可用于治疗各种疾病，包括病毒感染、癌症、真菌感染、细菌感染、微生物感染和相关疾病状态。本发明还涉及含有这些化合物的制药配方。此外，本发明还涉及在动物中特别是人类中治疗上述疾病的方法。
• Oxadiazolylthiazoles as novel and selective antifungal agents
  作者：Mohamed Hagras、Ehab A. Salama、Ahmed M. Sayed、Nader S. Abutaleb、Ahmed Kotb、Mohamed N. Seleem、Abdelrahman S. Mayhoub

  DOI：10.1016/j.ejmech.2020.112046

  日期：2020.3

  Studying the structure-activity relationships (SAR) of oxadiazolylthiazole antibiotics unexpectedly led us to identify ethylenediamine- and propylenediamine-analogs as potential antimycotic novel lead structures. Replacement of the ethylenediamine moiety for the lead compound 7 with cis-diaminocyclohexyl group (compound 18) significantly enhanced the antifungal activity. In addition to the high safety margin of 18 against mammalian cells, it showed highly selective broad-spectrum activity against fungal cells without inhibiting the human normal microbiota. The antifungal activity of 18 was investigated against 20 drug-resistant clinically important fungi, including Candida species, Cryptococcus, and Aspergillus fumigatus strains. In addition to the low MIC values that mostly ranged between 0.125 and 2.0 mu g/mL, compound 18 outperformed fluconazole in disrupting mature Candida biofilm. (C) 2020 Elsevier Masson SAS. All rights reserved.
• Inhibitors of hepatitis C virus NS3·4A protease 2. Warhead SAR and optimization
  作者：Robert B. Perni、Janos Pitlik、Shawn D. Britt、John J. Court、Lawrence F. Courtney、David D. Deininger、Luc J. Farmer、Cynthia A. Gates、Scott L. Harbeson、Rhonda B. Levin、Chao Lin、Kai Lin、Young-Choon Moon、Yu-Ping Luong、Ethan T. O'Malley、B.Govinda Rao、John A. Thomson、Roger D. Tung、John H. Van Drie、Yunyi Wei

  DOI：10.1016/j.bmcl.2004.01.022

  日期：2004.3

  The alpha-ketoamide warhead (e.g., 15) was found to be a practical replacement for aliphatic aldehydes in a series of HCV NS.4A protease inhibitors. Structure-activity relationships and prime side optimization are discussed. (C) 2004 Elsevier Ltd. All rights reserved.
• HUMAUS, R.;GRISS, G.;SAUTER, R.;GRELL, W.;KOBINGER, W.;PICHLER, L.
  作者：HUMAUS, R.、GRISS, G.、SAUTER, R.、GRELL, W.、KOBINGER, W.、PICHLER, L.

  DOI：——

  日期：——
• [EN] 5-HT2A AND/OR 5-HT2C RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR 5-HT2A ET/OU 5-HT2C
  申请人：[en]DIAMOND THERAPEUTICS INC.

  公开号：WO2022234339A2

  公开（公告）日：2022-11-10

  Provided herein are heterocyclic compounds, processes for their preparation, compositions comprising said compounds, and use in therapy. More particularly, the present disclosure relates to fluorinated and/or deuterated analog useful in the treatment of diseases, disorders or conditions treatable by modulating the 5-HT2 receptor subtypes.